B+
Bull case
20%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
DSGN
Design TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive four-week RESTORE-FA data showed dose-dependent increases in endogenous frataxin mRNA and protein alongside improvements across multiple clinical measures, while the company maintains substantial cash resources and advances DT-818 [#SEC-8K-2026-08-03].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.7.
What can break
Analyst revision, target-change, and post-print market-reaction evidence is limited, reducing confidence in near-term directional conclusions.
Momentum
77
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $25.00 · Bear $7.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $21.00
Why
Momentum77 · Δ7d -1.3
Value41 · Δ7d 0.0
Sentiment53 · Δ7d +4.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +4.7.
Contradictions & invalidation
- • Analyst revision, target-change, and post-print market-reaction evidence is limited, reducing confidence in near-term directional conclusions.
- • FECD Phase 2 biomarker data moved to 2027 because of delayed DT-168 eye-dropper supply [#SEC-8K-2026-08-03].
- • The thesis remains dependent on small clinical cohorts and future biomarker-to-clinical validation.
Catalyst clock
2026-08-03
Q2 2026 operating update and RESTORE-FA redesign
Lead driver: Sentiment · See AI snapshot
Momentum
77
9% active weight
Current posture
7d trendImproving
Δ7d
-1.3
Δ21d
-3.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
53
62% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
+2.4
Why this grade
Composite grade D. Momentum 76.6 / Value 41.2 / Sentiment 53.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$944.98M
Beta
1.64
Shares Out
62.58M
P/E (TTM) · Derived
-12.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-16.48
Rev YoY
-
EPS YoY
-3.9%
Gross Margin
-
Op Margin
-
Net Debt
-$218.31M
Current Ratio
18.86
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data